

# Saudi Arabia

## COUNTRY GENERAL INFORMATION

Total population:	34 218 169
Gender F/M (%):	42.3 / 57.7
Population, age group <15 / ≥ 15 years (%):	25 / 75
Life expectancy at birth (F/M, years):	76 / 73
GDP (PPP int \$):	49 040
Income status:	High income
Number of 1 <sup>st</sup> sub-national administrative level divisions, name:	20, Region



## EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	0	152	943	0
Number of relapses: <sup>1</sup>	0	No data	No data	N/A
<b>Total number of cases:</b>	<b>0</b>	<b>152</b>	<b>943</b>	<b>0</b>
Imported cases (#, %):	0, 0%	No data	No data	N/A
Gender distribution (% F):	N/A	No data	No data	No data
Age group distribution (% , <5 / 5-14 / >14):	N/A	No data	No data	No data
Incidence rate (cases/10 000 population in endemic areas):	N/A	0.2	0.33	N/A
Number of endemic 1 <sup>st</sup> sub-national administrative level divisions:	1	5	14	N/A
Population at risk (% , # at risk / total population): <sup>2</sup>	5% 1 637 361/ 34 218 169	22% 7 487 319/ 34 218 169	84% 28 627 925/ 34 218 169	N/A
Was there any outbreak?	No	No	No	N/A
Number of new foci: <sup>3</sup>	0	0	0	N/A



## Monthly distribution of new cases (January-December)

2019	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	0	0	0	0	0	0	0	0	0	0	0	0
ACL	15	22	26	23	8	12	6	4	6	10	11	9
ZCL	117	126	127	76	34	52	58	55	48	57	64	129

N/A not applicable; VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis



## Number of new cases and Incidence rate/10 000 at the national level from 2004 to 2019






<sup>1</sup>Relapse in this country is defined for VL as: "A patient who discharged with initial cure and returned with clinical signs of VL and positive parasitology" and for CL as: "Recurrence of clinical signs after complete cure"

<sup>2</sup>Defined as: "Number of people living in 1st sub-national administrative level endemic areas"

<sup>3</sup>Defined as: "In this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever"

## Disease distribution of new VL, ACL and ZCL cases at Regional level per 10 000 population (2019)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.  
Map production: WHO/UCN/NTD

## CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1978
Type of surveillance (CL / VL):	Integrated / Integrated
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin, Lambdacyhalothrin, Etofenoprox
Year latest national guidelines (CL / VL):	2019 / No data
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities (CL / VL):	No data / No data

## DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	0	No data	No data	N/A
Number of people screened passively for:	No data	No data	No data	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	N/A	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	N/A	No data	No data	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	No data	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	N/A	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	N/A	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

## TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Liposomal amphotericin B, Meglumine antimoniate, Sodium stibogluconate (SSG)

## INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	N/A	No data	No data
Initial cure rate (% , # cases initially cured / new cases):	N/A	No data	No data
Failure rate (% , # cases with treatment failure / new cases): <sup>4</sup>	N/A	No data	No data
Case fatality rate (% , # cases who died / new cases):	N/A	No data	No data

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

<sup>4</sup>Failure in this country is defined for VL as: "failure of improvement or deterioration during the treatment course" and for CL as: "Deterioration of clinical signs within the first 2 weeks, or absence of improvement after completion of treatment."